<VariationArchive RecordType="classified" VariationID="267200" VariationName="NC_000006.10:g.1543591_1675085del131495" VariationType="Deletion" Accession="VCV000267200" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-04-25" DateCreated="2016-10-22" MostRecentSubmission="2016-10-22">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="262042" VariationID="267200">
      <GeneList>
        <Gene Symbol="FOXC1" FullName="forkhead box C1" GeneID="2296" HGNC_ID="HGNC:3800" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>6p25.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="1609915" stop="1613897" display_start="1609915" display_stop="1613897" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="1610680" stop="1614131" display_start="1610680" display_stop="1614131" Strand="+" />
          </Location>
          <OMIM>601090</OMIM>
          <Haploinsufficiency last_evaluated="2020-07-29" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FOXC1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-07-29" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FOXC1">No evidence available</Triplosensitivity>
        </Gene>
        <Gene Symbol="GMDS" FullName="GDP-mannose 4,6-dehydratase" GeneID="2762" HGNC_ID="HGNC:4369" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>6p25.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="1623806" stop="2245605" display_start="1623806" display_stop="2245605" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="1624034" stop="2245867" display_start="1624034" display_stop="2245867" Strand="-" />
          </Location>
          <OMIM>602884</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000006.10:g.1543591_1675085del131495</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>6p25.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="1598592" stop="1730086" display_start="1598592" display_stop="1730086" variantLength="131495" />
        <SequenceLocation Assembly="NCBI36" AssemblyAccessionVersion="GCF_000001405.12" AssemblyStatus="previous" Chr="6" Accession="NC_000006.10" start="1543591" stop="1675085" display_start="1543591" display_stop="1675085" variantLength="131495" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="NCBI36" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.10" sequenceAccession="NC_000006" sequenceVersion="10" change="g.1543591_1675085del131495" Assembly="NCBI36">
            <Expression>NC_000006.10:g.1543591_1675085del131495</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.11" sequenceAccession="NC_000006" sequenceVersion="11" change="g.1598592_1730086del" Assembly="GRCh37">
            <Expression>NC_000006.11:g.1598592_1730086del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="essv25893584" DB="dbVar" />
        <XRef ID="essv25893593" DB="dbVar" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000006.10:g.1543591_1675085del131495 AND Congenital aniridia" Accession="RCV000257274" Version="1">
        <ClassifiedConditionList TraitSetID="17309">
          <ClassifiedCondition DB="MedGen" ID="C0003076">Congenital aniridia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2016-10-22" MostRecentSubmission="2016-10-22">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="17309" Type="Finding" ContributesToAggregateClassification="true">
            <Trait ID="36295" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Congenital aniridia</ElementValue>
                <XRef ID="Congenital+aniridia/8046" DB="Genetic Alliance" />
                <XRef ID="69278003" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Aniridia</ElementValue>
                <XRef ID="HP:0000526" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0019172" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">AN</ElementValue>
                <XRef Type="MIM" ID="106210" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">PAX6-related aniridia occurs either as an isolated ocular abnormality or as part of the Wilms tumor-aniridia-genital anomalies-retardation (WAGR) syndrome. Aniridia is a pan ocular disorder affecting the cornea, iris, intraocular pressure (resulting in glaucoma), lens (cataract and lens subluxation), fovea (foveal hypoplasia), and optic nerve (optic nerve coloboma and hypoplasia). Individuals with aniridia characteristically show nystagmus and impaired visual acuity (usually 20/100 - 20/200); however, milder forms of aniridia with subtle iris architecture changes, good vision, and normal foveal structure do occur. Other ocular involvement may include strabismus and occasionally microphthalmia. Although the severity of aniridia can vary between and within families, little variability is usually observed in the two eyes of an affected individual. WAGR syndrome. The risk for Wilms tumor is 42.5%-77%; of those who develop Wilms tumor, 90% do so by age four years and 98% by age seven years. Genital anomalies in males can include cryptorchidism and hypospadias (sometimes resulting in ambiguous genitalia), urethral strictures, ureteric abnormalities, and gonadoblastoma. While females typically have normal external genitalia, they may have uterine abnormalities and streak ovaries. Intellectual disability (defined as IQ &lt;74) is observed in 70%; behavioral abnormalities include attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, anxiety, depression, and obsessive-compulsive disorder. Other individuals with WAGR syndrome can have normal intellect without behavioral problems.</Attribute>
                <XRef ID="NBK1360" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301534</ID>
                <ID Source="BookShelf">NBK1360</ID>
              </Citation>
              <XRef ID="C0003076" DB="MedGen" />
              <XRef ID="MONDO:0019172" DB="MONDO" />
              <XRef Type="primary" ID="HP:0000526" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="621609" SubmissionDate="2016-10-04" DateLastUpdated="2016-10-22" DateCreated="2016-10-22">
        <ClinVarSubmissionID localKey="essv25893584|HPO:HP:0000526" submittedAssembly="NCBI36" />
        <ClinVarAccession Accession="SCV000267949" DateUpdated="2016-10-22" DateCreated="2016-10-22" Type="SCV" Version="1" SubmitterName="EVA, EMBL-EBI" OrgID="505264" OrganizationCategory="other" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="505972" SubmitterName="MRC Institute of Genetics and Molecular Medicine, University of Edinburgh" Type="secondary" OrganizationCategory="laboratory" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <NamePlatform>Roche Nimblegen 135k and Agilent targeted</NamePlatform>
              <TypePlatform>Oligo aCGH</TypePlatform>
              <Description>Each 5q22-23 deletion was ascertained via routine clinical genetics investigations within a regional genetics service laboratory using array-based comparative genomic hybridisation (aCGH) with or without conventional cytogenetic analysis and fluorescent in situ hybridisation (FISH) to metaphase chromosomes. The FISH and aCGH analyses were performed in different clinical and research laboratories. The overlapping phenotype was noted following the submission of deletions from different centres to the DECIPHER database (http://decipher.sanger.ac.uk). A panel of 25 PRS cases with no deletions detected on aCGH were screened for intragenic mutations in FBN2 and PHAX. This study was performed under ethical approval provided by the UK Multiregional Ethics Committee (Reference: 06/MRE00/77). (PMID:25195018)</Description>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <NamePlatform>Roche Nimblegen 135k and Agilent targeted</NamePlatform>
              <TypePlatform>Oligo aCGH</TypePlatform>
              <Description>Each 5q22-23 deletion was ascertained via routine clinical genetics investigations within a regional genetics service laboratory using array-based comparative genomic hybridisation (aCGH) with or without conventional cytogenetic analysis and fluorescent in situ hybridisation (FISH) to metaphase chromosomes. The FISH and aCGH analyses were performed in different clinical and research laboratories. The overlapping phenotype was noted following the submission of deletions from different centres to the DECIPHER database (http://decipher.sanger.ac.uk). A panel of 25 PRS cases with no deletions detected on aCGH were screened for intragenic mutations in FBN2 and PHAX. This study was performed under ethical approval provided by the UK Multiregional Ethics Committee (Reference: 06/MRE00/77). (PMID:25195018)</Description>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="NCBI36" Chr="6" start="1543591" stop="1675085" variantLength="131495" />
          </Location>
          <XRefList>
            <XRef DB="dbVar" ID="essv25893584" Type="dbVarVariantCallId" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000006.10:g.1543591_1675085del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Finding">
          <Trait Type="Finding">
            <XRef DB="HP" ID="HP:0000526" />
          </Trait>
        </TraitSet>
        <StudyName>Ansari2015</StudyName>
        <StudyDescription>Genetic Analysis of Individuals with Aniridia or Gillespie Syndrome</StudyDescription>
        <SubmissionNameList>
          <SubmissionName>Ansari</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="621609" TraitType="Finding" MappingType="XRef" MappingValue="HP:0000526" MappingRef="HP">
        <MedGen CUI="C0003076" Name="Congenital aniridia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

